arrow
M

Michael Gnant

Medical University of Vienna
H指数:102
被引数:7.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer

Xpert乳腺癌洞察测试可预测ER阳性、HER2阴性早期乳腺癌的远处复发和总生存期

2026-07-010
OAAI
Body Mass Index in Postmenopausal Women with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer: An Exploratory Analysis of the LORELEI trial.

雌激素受体阳性、HER2阴性早期乳腺癌绝经后女性中的体重指数:LORELEI试验的探索性分析

2026-06-120
PRE
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer

更正:在PALLAS全球随机临床试验中,palbociclib对早期乳腺癌患者正在进行辅助内分泌治疗的治疗依从性的影响

2026-02-180
PRE
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34

ABCSG试验34中乳腺癌患者诊断性核心活检样本中的ESR1、PGR、ERBB2和MKi67 mRNA表达

2025-10-300
OAAI
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

新辅助系统性乳腺癌治疗试验中局部区域治疗报告的核心结局指标集

2025-10-280
OA
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

帕博西利联合辅助内分泌疗法在早期乳腺癌中的应用:全球多中心、开放标签、随机III期PALLAS试验(ABCSG-42/AFT-05/PrE0109/BIG-14-13)五年随访分析

2025-10-170
OAAI
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

根据癌症风险和患者偏好调整治疗:2025年圣加仑国际早期乳腺癌共识声明,关于为早期乳腺癌患者个体化治疗。

2025-10-080
OAAI
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

乳腺癌患者接受阿贝西利或瑞博西利辅助治疗的患病率与预后:一项全国性基于人群的研究

2025-09-290
OAAI
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST
IF7.9
2025-04-010
OAAI
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy☆

PENELOPE-B试验的最终生存结果,该试验探讨了帕博西利(palbociclib)与安慰剂对比用于新辅助化疗后具有高危HR+/HER2−乳腺癌且存在残留病灶患者的治疗。

2025-03-240
PRE
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
2025-03-010
PRE